Trial Profile

A Phase 2 Study of Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary) ; Anthracenes; Cyclophosphamide; Dexamethasone; Doxorubicin; Doxorubicin liposomal; Glucocorticoids; Prednisone; Rituximab; Vinca alkaloids; Vincristine; Vindesine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms ORIENT

14 Jun 2024 Results presented in an InnoCare Pharma Media Release.
14 Jun 2024 According to an InnoCare Pharma media release, results from this trial were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
15 Jun 2023 Results (cutoff date (February 10, 2023, n=10) efficacy and safety of O plus R-CHOP-like (O+R-CHOP) for previously untreatednon-GCB DLBCL pts who benefited from induction therapy of O plus R (OR) presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com